Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation
Friday, May 31, 2024
6:30 PM – 7:30 PM CT
Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific
PROGRAM FEATURES
- Online personalized quality-improvement poster-generation portal
- Downloadable whiteboard animations
FACULTY
 |
John Marshall, MD Physician Executive Director MedStar Health Division Director Integrated Hematology Oncology Washington, DC |
 |
Ronan J. Kelly, MD Director, Charles A. Sammons Cancer Center Chief of Oncology Baylor Scott & White Health System (NTx) W.W. Caruth Jr. Endowed Chair of Immunology Baylor University Medical Center Dallas, Texas Clinical Professor Texas A&M University College of Medicine Adjunct Associate Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Baltimore, Maryland Professor, Clinical Sciences Division at the Translational Genomics Research Institute (TGEN) Phoenix, Arizona |
PROGRAM OVERVIEW
With the recent discovery of HER2-targeted therapy’s efficacy in patients with gastrointestinal cancers, the community oncology team is further challenged to keep abreast of the most recent data. That in concert with the new trial findings of patients with either GEJ or GC who respond to HER2-targeted antibody-drug conjugate therapy in spite of HER2-low levels of expression continue to challenge the community oncologist. The application of this new data can be supported through the understanding and use of practice guidelines which will be reviewed along with their supporting clinical trial findings. Finally, the knowledge to both recognize and treat adverse events associated with antibody-drug conjugates in the gastrointestinal cancer population is essential for the optimal care of these patients.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community medical oncologists, pathologists and others (eg, nurse practitioner, pharmacist, physician assistant, oncology nurse) involved in the management of patients with gastric and gastroesophageal junction cancers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize relevance of HER2 expression in GEJ and advanced gastric cancer management, including best practices for assessment.
- Evaluate current clinical trial findings informing available and emerging treatment strategies in gastric and GEJ cancer management.
- Recognize appropriate strategies for monitoring and management of potential toxicities associated with HER2-targeted antibody-drug conjugate therapies, including interstitial lung disease.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the live event at [email protected]
